Generic FDC drug vs two monoproduct drug or vs "originator" FDC drug? [Design Issues]

posted by Beholder  – Russia, 2018-09-04 11:12 (914 d 05:45 ago) – Posting: # 19234
Views: 3,071

Hello to everybody!

There is generic FDC drug named AB which is intended to be studied in BE study. There are two options to choose reference drug (s) for that study:
1. two separate monoproducts - named drug A and drug B. Both drugs considered as reference drugs
2. "original" FDC drug named AB which is also considered as reference drug.
Which drug (s) to choose as reference drug (s)? What would be your opinion?
THX in advance.

Best regards
Beholder

Complete thread:

Activity
 Admin contact
21,371 posts in 4,463 threads, 1,495 registered users;
online 3 (0 registered, 3 guests [including 3 identified bots]).
Forum time: Saturday 15:58 CET (Europe/Vienna)

If debugging is the process of removing bugs,
then programming must be the process of putting them in.    Edsger W. Dijkstra

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5